We are delighted to inform you that the Company has received Letter of Award for supply of bivalent Oral Polio Vaccine (bOPV) to UNICEF in 10 and 20 dose presentation worth ~US$8.205 million ....
ORDERS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 05 Aug 2026, 09:39 AM IST · BSE ID: 97730696-ee74-4c72-99ea-5bba933013cb
View Original BSE Filing (PDF)
💡
In Simple Terms
Panacea Biotec won a contract to supply polio vaccine to UNICEF for approximately US$8.2 million in 2028.
🤖 AI Summary
- Panacea Biotec awarded supply contract for bivalent Oral Polio Vaccine to UNICEF.
- Order value totals approximately US$8.205 million (~Rs. 78.24 Crore) for Calendar Year 2028.
- Award is under a Long-Term Agreement for bOPV supply initiated April 1, 2026.
- UNICEF is an international entity awarding this supply contract to the company.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Order Value (US$)
US$8.205 million
Order Value (Rs.)
Rs. 78.24 Crore
Execution Period
Calendar Year 2028
🏢 How This Affects the Company
This order strengthens Panacea Biotec's position in the global vaccine supply chain and provides significant revenue visibility for Calendar Year 2028.
The US$8.205 million order contributes to the company's order book, impacting future revenue streams.
The order necessitates continued production and quality assurance for bivalent Oral Polio Vaccine to meet UNICEF's requirements.
👥 What This Means For Shareholders
✅
Action Required
No action is required by shareholders based on this announcement.
👤
Who Is Affected
All shareholders are informed of a significant order win impacting the company's future revenue.
🔍
Management Signal
Management continues to secure large, long-term supply contracts with major international organizations, signaling commitment to vaccine export business.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
UNICEF order execution status updates
Future announcements on other UNICEF contract tranches
Company's financial results reporting revenue from this order
LOW RISK
The order is confirmed via a Letter of Award from a reputable international body (UNICEF).
💡 Investor Takeaway
Panacea Biotec secured a US$8.205 million (~Rs. 78.24 Crore) order from UNICEF for bivalent Oral Polio Vaccine supply in CY2028, as part of an ongoing long-term agreement.
⚖️ Strengths & Concerns
✅ Positives
- Secured a significant international order of US$8.205 million from UNICEF for bOPV supply in CY2028.
- Order is part of an established Long-Term Agreement with UNICEF, indicating ongoing relationship.
📅 Company Track Record
In April 2026, Panacea Biotec announced receiving a Letter of Award from UNICEF for bOPV supply under a long-term agreement spanning April 2026 to March 2030.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What is the value of the order Panacea Biotec received from UNICEF?
Panacea Biotec received a Letter of Award for supply of bivalent Oral Polio Vaccine worth approximately US$8.205 million (~Rs. 78.24 Crore).
Who awarded the contract to Panacea Biotec?
The contract was awarded by the United Nations International Children's Emergency Fund (UNICEF), an international entity.
When is the supply for this UNICEF order expected to be executed?
The supply of bivalent Oral Polio Vaccine is expected to be executed in Calendar Year 2028.
Is this a new contract or part of a larger agreement for Panacea Biotec with UNICEF?
This award is in continuation of an earlier intimation regarding a Long-Term Agreement with UNICEF for bOPV supply starting from April 1, 2026.
Questions based on this BSE filing only. For information purposes.